Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... , Oct. 27, 2014 Kalorama Information says ... Ebola concern in the United States ... The healthcare market researcher said the FDA,s Emergency Use Authorization ... diagnostic tests for the detection of the Ebola virus ... useful.  Kalorama routinely assess the IVD industry and its ...
(Date:10/27/2014)... Florida (PRWEB) October 27, 2014 ... at reducing and eliminating several types of pediatric ... not been achieved in over 30 years of ... Noah's Light Foundation, proves that one mom's determination ... diagnosed just before Halloween trick-or-treating, and it’s only ...
(Date:10/27/2014)... HORSHAM, Pa. , Oct. 27, 2014 /PRNewswire/ ... Colitis Foundation of America (CCFA) announced today the ... , an educational campaign designed ... bowel diseases (IBD) on the paired role of ... To view the multimedia assets associated with ...
(Date:10/26/2014)... The report "Protective Coatings Market by ... Trends & Forecast to 2019", defines and segments the ... volume consumed and value generated. The protective coatings consumption ... to 6,701.3 KT by 2019, at a CAGR of ... data tables and 22 figures spread through 219 slides ...
Breaking Biology Technology:Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4
... provided people with many items such as iPods, ... audio capabilities. Technology is evolving so quickly that ... years ago are now taken for granted. , ... understand how technology may evolve when entering into ...
... series of articles on raising capital from investors. This installment focuses ... time when raising equity capital, the offering terms are summarized in ... When dealing with angel investors , it is typical for ... angel investors will want to negotiate the initial term sheet, especially ...
... . - Oren Harari is coming to Milwaukee next ... of innovation. , ,Not just to manufacturers, who he will be ... to business organizations in a number of sectors, including technology. , ... to Compete in a Copycat Economy , he intends to deploy ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 2Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 3
(Date:10/29/2014)... kind of stem cell, those referred to as ,facultative, ... is apparently nothing that differentiates these cells from the ... they retain the capacity to become stem cells again. ... an organ that hosts cells that stimulate tissue growth, ... case of a transplant. Knowledge of the underlying ...
(Date:10/29/2014)... Cancer Genomics of the Kidney consortium ( CAGEKID ... and exposure to aristolochic acid, an ingredient in ... Nature Communications , have important implications for public ... people every year, and in Central Europe incidence ... the International Cancer Genome Consortium (ICGC), has been ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
Breaking Biology News(10 mins):A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Kidney cancer in Central Europe 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... days over what they eat, and whether horse meat ... been dominating headlines globally - calling for new ... successful food identification and authentication. As companies and manufacturers ... the gullible public, it is estimated that up to ...
... 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and ... build a pipeline of therapeutic drugs aimed at ... needs. Under this agreement, Mayo Clinic scientists will ... for Chemical Genomics (Prebys Center) to conduct early-stage ...
... increasingly resembles lusher latitudes to the south, according to ... land surface and newly improved satellite data sets. ... the relationship between changes in surface temperature and vegetation ... Ocean. Results show temperature and vegetation growth at northern ...
Cached Biology News:DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement 2Amplified greenhouse effect shifts north's growing seasons 2Amplified greenhouse effect shifts north's growing seasons 3
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Homo sapiens formin-like...
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: